Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.

Abstract

The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management of localized disease, post-treatment monitoring, and treatment of recurrence and advanced disease. The Guidelines sections included in this article focus on the management of metastatic castration-sensitive disease, nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC). Androgen deprivation therapy (ADT) with treatment intensification is strongly recommended for patients with metastatic castration-sensitive prostate cancer. For patients with nonmetastatic CRPC, ADT is continued with or without the addition of certain secondary hormone therapies depending on prostate-specific antigen doubling time. In the mCRPC setting, ADT is continued with the sequential addition of certain secondary hormone therapies, chemotherapies, immunotherapies, radiopharmaceuticals, and/or targeted therapies. The NCCN Prostate Cancer Panel emphasizes a shared decision-making approach in all disease settings based on patient preferences, prior treatment exposures, the presence or absence of visceral disease, symptoms, and potential side effects.

• Authors: Edward M Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Daniel Barocas, Rhonda Bitting, Alan Bryce, Brian Chapin, Heather H Cheng, Anthony Victor D'Amico, Neil Desai, Tanya Dorff, James A Eastham, Thomas A Farrington, Xin Gao, Shilpa Gupta, Thomas Guzzo, Joseph E Ippolito, Michael R Kuettel, Joshua M Lang, Tamara Lotan, Rana R McKay, Todd Morgan, George Netto, Julio M Pow-Sang, Robert Reiter, Mack Roach, Tyler Robin, Stan Rosenfeld, Ahmad Shabsigh, Daniel Spratt, Benjamin A Teply, Jonathan Tward, Richard Valicenti, Jessica Karen Wong, Dorothy A Shead, Jenna Snedeker, Deborah A Freedman-Cass
• Journal: Journal of the National Comprehensive Cancer Network : JNCCN (J Natl Compr Canc Netw) Vol. 21 Issue 10 Pg. 1067-1096 (10 2023) ISSN: 1540-1413 [Electronic] United States
• PMID: 37856213 (Publication Type: Journal Article, Practice Guideline)

Chemical References

• Androgen Antagonists
• Hormones

Topics

• Humans
• Male
• Androgen Antagonists (therapeutic use)
• Hormones (therapeutic use)
• Prostatic Neoplasms (therapy, drug therapy)
• Prostatic Neoplasms, Castration-Resistant (therapy, drug therapy)